Targeting tumor‐associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Tumor-associated fibroblasts are key regulators of tumorigenesis. In contrast to tumor cells, which are genetically unstable and mutate frequently, the presence of genetically more stable fibroblasts in the tumor-stromal compartment makes them an optimal target for cancer immunotherapy. These cells are also the primary source of collagen type I, which contributes to decreased chemotherapeutic drug uptake in tumors and plays a significant role in regulating tumor sensitivity to a variety of chemotherapies. To specifically kill tumor-associated fibroblasts, we constructed an oral DNA vaccine targeting fibroblast activation protein (FAP), which is specifically overexpressed by fibroblasts in the tumor stroma. Through CD8+ T cell-mediated killing of tumor-associated fibroblasts, our vaccine successfully suppressed primary tumor cell growth and metastasis of multidrug-resistant murine colon and breast carcinoma. Furthermore, tumor tissue of FAP-vaccinated mice revealed markedly decreased collagen type I expression and up to 70% greater uptake of chemotherapeutic drugs. Most importantly, pFap-vaccinated mice treated with chemotherapy showed a 3-fold prolongation in lifespan and marked suppression of tumor growth, with 50% of the animals completely rejecting a tumor cell challenge. This strategy opens a new venue for the combination of immuno- and chemotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, depleting fibroblast activation protein (FAP)+ CAFs via a FAP vaccine decreases collagen density and improves chemoresistance in mouse models [99].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
High Interstitial Fluid Pressure - an Obstacle in Cancer Therapy
Heldin, C.-H., Rubin, K., Pietras, K., & Östman, A. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1456 · Cited by 2,222
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
The myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Transport of molecules in the tumor interstitium: a review.
Jain, R. K. (1987) · PubMed · Cited by 1,378
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Stromal Effects on Mammary Gland Development and Breast Cancer
Wiseman, B. S., & Werb, Z. (2002) · Science · doi:10.1126/science.1067431 · Cited by 923
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Cited by
Items 401–500 of 648
Wang, M., Zhao, Y., Xu, K., Liu, C., Zhong, H., Wu, Y., Zhang, K., & Wei, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617968 · Cited by 34
Cai, F., Li, Z., Wang, C., Xian, S., Xu, G., Peng, F., Wei, Y., & Lü, Y. (2013) · BMB Reports · doi:10.5483/bmbrep.2013.46.5.172 · Cited by 23
“mor growth and metastasis, as well as increasing intratumoral uptake of chemotherapeutic drugs in multidrug-resistant murine colon and breast carcinoma models (17).”
BackgroundPro-Metastatic Tumor–Stroma Interactions in Breast Cancer
Gangadhara, S., Barrett-Lee, P. J., Nicholson, R. I., & Hiscox, S. (2012) · Future Oncology · doi:10.2217/fon.12.134 · Cited by 29
Hemalatha, S. K., Sengodan, S. K., Nadhan, R., Usha, J. D. S., Sushama, R. R., Somasundaram, V., Thankappan, R., Rajan, A., Latha, N. R., Varghese, G. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-32370-w · Cited by 23
Research progress in tumor targeted immunotherapy
Fang, Y., Yu, A., Ye, L., & Zhai, G. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1882992 · Cited by 23
Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies
Grassi, E., Ghiandai, V., & Persani, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10071455 · Cited by 27
Gambara, G., Gaebler, M., Keilholz, U., Regenbrecht, C. R. A., & Silvestri, A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00077 · Cited by 25
“…role tumor microenvironment plays in cancer development as well as in chemo-resistance, new therapeutic approaches have been developed to target not only tumor cells but also components of this supporting environment (Loeffler et al., 2006; Rossler et al., 2008; Dougan and Dranoff, 2009).”
BackgroundEnhanced nanodrug delivery in tumors after near‐infrared photoimmunotherapy
Inagaki, F. F., Furusawa, A., Choyke, P. L., & Kobayashi, H. (2018) · Nanophotonics · doi:10.1515/nanoph-2019-0186 · Cited by 23
Hang, Y., Liu, Y., Teng, Z., Cao, X., & Zhu, H. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01841-2 · Cited by 25
“Similar phenomena can be detected in breast and colon cancer cell models [52].”
BackgroundDorst, D. N., Smeets, E., Klein, C., Frielink, C., Geijs, D. J., Trajkovic‐Arsic, M., Cheung, P. F., Stommel, M. W. J., Gotthardt, M., Siveke, J. T., et al. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00453 · Cited by 23
Armstrong, S., Narendrula, R., Guo, B., Parissenti, A. M., McCallum, K. L., Cull, S., & Lannér, C. (2012) · Journal of Ovarian Research · doi:10.1186/1757-2215-5-40 · Cited by 22
Cancer Microenvironment and Cancer Vaccine
Ding, Z., Zou, X.-L., & Wei, Y.-Q. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0107-x · Cited by 22
Characterization of Tumor-Derived Pancreatic Stellate Cells
Farrow, B. J., Rowley, D. R., Dang, T., & Berger, D. H. (2009) · Journal of Surgical Research · doi:10.1016/j.jss.2009.03.064 · Cited by 26
Wu, X., Lü, W., Zhang, W., Zhang, D., Mei, H., Zhang, M., Cui, Y., & Zhuo, Z. (2023) · Aging · doi:10.18632/aging.205205 · Cited by 24
“There are also novel FAP-targeted immunotherapies, such as DNA vaccination [43], chimeric antigen receptor T cells [44, 45] or lysing adenovirus [46, 47].”
BackgroundTargeting fibroblast activation protein with chimeric antigen receptor macrophages
Mao, Y., Chen, Y. M., Zhang, S., Zeng, Q., Wang, J., Sheng, C., & Chen, S. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116604 · Cited by 24
Qiu, X., Geng, F., Zhang, F.-F., Liu, C., Xu, P., Lu, Z.-Z., Zhang, H., Kong, W., & Yu, X. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.07.054 · Cited by 21
Galván, J. A., Wiprächtiger, J., Slotta‐Huspenina, J., Feith, M., Ott, K., Kröll, D., Seiler, C. A., & Langer, R. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02714-6 · Cited by 23
Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors
Date, V., & Nair, S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1819978 · Cited by 22
“sent on these fibroblasts which differentiates them from its non-cancer-related counterparts [111].”
BackgroundAnticancer therapeutics: A surge of new developments increasingly target tumor and stroma
Broxterman, H. J., & Georgopapadakou, N. H. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.07.001 · Cited by 23
Targeting the Stroma by T Cells to Limit Tumor Growth
Zhang, B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2414 · Cited by 21
“Others have used antigens directly expressed by stromal cells [vascular endothelial growth factor receptor by endothelial cells (20), fibroblast activation protein by fibroblasts ( 21 ), or legumain by macrophages (22)] as targets for therapy.”
BackgroundHao, Y., Zhang, L., He, J., Guo, Z., Ying, L., Xu, Z., Zhang, J., Lu, J., & Wang, Q. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061754 · Cited by 20
“Myofibroblasts are key mediators of tumor growth including proliferation, invasion and metastasis, and can contribute to chemoresistance [5,6,7].”
BackgroundRasel, M. S. I., Mohona, F. A., Akter, W., Kabir, S., Chowdhury, A. A., Chowdhury, J. A., Hassan, M. A., Mamun, A. A., Ghose, D. K., Ahmad, Z., et al. (2022) · Journal of Oncology · doi:10.1155/2022/9396760 · Cited by 27
“Also, cancerassociated fibroblasts (CAFs) lead to diminished uptake of drugs by upregulating the synthesis of extracellular matrix (ECM), ECM remodelling by matrix metalloproteinase (MMP), post-translational modifications, and several other ECM-mediated malignant changes [59, 60].”
BackgroundYang, Z., Jin, P., Xu, S., Zhang, T., Yang, X., Li, X., Xiao, W., Sun, C., Chen, G., Ma, D., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.11.026 · Cited by 20
Fibroblasts in cancer: Defining target structures for therapeutic intervention
Boesch, M., Baty, F., Rumpold, H. F., Sopper, S., Wolf, D. G. F., & Brutsche, M. H. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.06.003 · Cited by 20
Dao, N. V., Ercole, F., Urquhart, M. C., Kaminskas, L. M., Nowell, C. J., Davis, T. P., Sloan, E. K., Whittaker, M. R., & Quinn, J. F. (2021) · Biomaterials Science · doi:10.1039/d0bm01544j · Cited by 21
Khotskaya, Y. B., Beck, B. H., Hurst, D. R., Han, Z., Xia, W., Hung, M., & Welch, D. R. (2013) · Molecular Carcinogenesis · doi:10.1002/mc.22068 · Cited by 21
Wang, Q., Song, C. W., Zhao, C., Wei, X., De-li, L., Wu, Q., Li, J., & Yang, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145006 · Cited by 24
Yushkov, B., Черешнев, В. А., Korneva, E. A., Yushkova, V., & Sarapultsev, A. (2025) · Cells · doi:10.3390/cells14130981 · Cited by 24
Pompili, S., Vetuschi, A., Sferra, R., & Cappariello, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.933675 · Cited by 19
Ren, S.-N., Zhang, Z.-Y., Guo, R.-J., Wang, D., Chen, F., Chen, X., & Fang, X. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i13.1911 · Cited by 22
Unraveling the role of cancer-associated fibroblasts in colorectal cancer
Cui, J., Ma, J., Gao, X., Sheng, Z.-M., Pan, Z., Shi, L., & Zhang, B. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i12.4565 · Cited by 20
Ke, Z. O. U., Ju, J., & Xie, H. J. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00554.x · Cited by 22
Chen, M., Xu, G., Fan, M., Jia, H., Xiao, L., & Lang, J. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1687498 · Cited by 20
“reported an oral vaccine targeting FAPa that can specifically kill CAFs and inhibit multi-drug-resistant tumour growth and metastases in murine breast cancer and colon cancer [20].”
BackgroundCui, C., Zhang, T., Lin, Q., Huang, T., Rao, E., Du, J., & Fu, L. (2024) · MedComm – Oncology · doi:10.1002/mog2.70004 · Cited by 20
Santi, M. D., Zhang, M., Asam, K. R., Yu, G., Dong, P. M., Sheehan, D. H., Aouizerat, B. E., Thomas, C. M., Viet, C. T., & Ye, Y. (2024) · Journal of Pain · doi:10.1016/j.jpain.2024.104615 · Cited by 18
Effect of cancer-associated fibroblasts on radiosensitivity of cancer cells
Ji, X., Zhu, X., & Lu, X. (2017) · Future Oncology · doi:10.2217/fon-2017-0054 · Cited by 19
Hintz, H. M., Snyder, K. M., Wu, J., Hullsiek, R., Dahlvang, J. D., Hart, G. T., Walcheck, B. K., & LeBeau, A. M. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0178 · Cited by 20
“Previous studies have shown a therapeutic effect from combination therapies that target both the tumor stroma and malignant cells compared with either monotherapy alone (12, 34, 35).”
BackgroundCCL2/CCR2 signaling pathway in tumorigenesis and metastasis (Review)
Zhang, Y., Fan, B., Yang, H., Chen, G., Huang, Z., Li, Y., Ma, X., Wang, T., Wang, W., Cai, L., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15344 · Cited by 22
Cancer-associated fibroblasts: central players in cancer hallmarks and therapeutic resistance
Lu, Y., Wu, Y., Xu, X., Feng, Y., & Wang, N. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02516-1 · Cited by 18
“A DNA vaccine that induces immune responses to FAP significantly reduced FAP + CAF numbers and was associated with increased intratumoral chemo uptake and enhanced T cell activity, overcoming immune tolerance in mouse models of colon and breast cancer [121].”
Wang, J. Y., Min, A., Gao, S., & Tang, Z. (2013) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12098 · Cited by 19
Miao, Y., Deng, Y., Liu, J., Wang, J., Hu, B., Hao, S., Wang, H., Zhang, Z., Jin, Z., Zhang, Y., et al. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14024 · Cited by 16
The origins, roles and therapies of cancer associated fibroblast in liver cancer
Zulaziz, N., Chai, S. J., & Lim, K. P. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1151373 · Cited by 18
“DNA vaccine – – Induced CD8 T cells, suppressed tumor growth in breast and colon murine models (94)”
BackgroundLiu, L., Zhang, Y., Liu, H., Yang, J., Tian, Q., Chueakula, N., Ramasamy, S. K., Verma, N. K., Cheung, C., & Kusumbe, A. P. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-4744 · Cited by 18
“Additionally, an oral DNA vaccine targeting FAP has shown promise in enhancing CD8 + T cell–mediated CAF killing, reducing tumor growth and metastasis in pre-clinical models (68).”
Ye, Z., Li, Z., Jin, H., & Qian, Q. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_3 · Cited by 19
Walter, S. G., Scheidt, S., Nißler, R., Gaisendrees, C., Zarghooni, K., & Schildberg, F. A. (2021) · Cancers · doi:10.3390/cancers13061466 · Cited by 16
“Targeting of CAFs using a DNA vaccine directed on the FAP demonstrated tumor suppression and reduced the potential for metastasis in CRC and breast cancer models [47].”
BackgroundInfluentialA simple 3D cryogel co-culture system used to study the role of CAFs in EMT of MDA-MB-231 cells
Zhang, G., Song, X., Mei, J., Ye, G., Wang, L., Yu, L., Xing, M. M. Q., & Qiu, X. (2017) · RSC Advances · doi:10.1039/c6ra28721b · Cited by 18
Li, J., Zeng, Z., Jiang, X., Zhang, N., Gao, Y., Luo, Y., Sun, W., Li, S., Ren, J., Gong, Y. Q., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-75541-4 · Cited by 16
Logsdon, D. K., Beeghly, G. F., & Munson, J. M. (2017) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-017-0498-3 · Cited by 18
Huang, Y., Wu, Y., Liu, H., Chen, Y., Xie, Q., & Yin, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616618 · Cited by 18
“Similarly, FAP vaccination decreased tumor growth, suppressed metastasis, and increased survival (96 – 99).”
Next Viable Routes to Targeting Pancreatic Cancer Stemness: Learning from Clinical Setbacks
Tsai, K. K., Chan, T., & Shaked, Y. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050702 · Cited by 17
“This gene therapy approach has been shown to suppress tumor growth and metastasis in murine models of CRC and breast cancer [124].”
BackgroundZuo, T., Zhang, J., Yang, J., Xu, R. F., Hu, Z., Wang, Z., Deng, H., & Shen, Q. (2021) · Biomaterials Science · doi:10.1039/d0bm01878c · Cited by 15
Jin, J., Barnett, J. D., Krishnamachary, B., Mironchik, Y., Luo, C. K., Kobayashi, H., & Bhujwalla, Z. M. (2022) · Cancer Science · doi:10.1111/cas.15601 · Cited by 18
Maspin influences response to doxorubicin by changing the tumor microenvironment organization
Triulzi, T., Ratti, M., Tortoreto, M., Ghirelli, C., Aiello, P., Regondi, V., Modica, M. D., Cominetti, D., Carcangiu, M. L., Moliterni, A., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28608 · Cited by 15
“Moreover, collagen I released by fibroblasts decreases drug uptake by cancer cells, thus mediating resistance to chemotherapy,(33) and drug penetration can be enhanced by decreasing the fibroblast pool and consequently the extracellular matrix produced.(34,35) In this context, we found that although DXR diffusion occu…”
BackgroundPirfenidone enhances the efficacy of combined radiation and sunitinib therapy
Choi, S., Nam, J.-K., Jang, J.-H., Lee, H., & Lee, Y. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.107 · Cited by 17
“Resistance to chemo- or radiotherapy is associated with cancer fibroblasts [26,27].”
BackgroundTokhanbigli, S., Haghi, M., Dua, K., & Oliver, B. G. G. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.55 · Cited by 24
Transcriptional mimicry by tumor-associated stroma
Kim, H., & Verhaak, R. G. W. (2015) · Nature Genetics · doi:10.1038/ng.3255 · Cited by 14
Bozorgi, A., Bozorgi, M., & Khazaei, M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00700-w · Cited by 15
“Most epithelial malignancies, including breast, pancreatic, lung and brain cancers, are rich in FAP-reactive fibroblasts, rendering them suitable for immunetargeting coupled with tumor growth suppression and enhanced chemotherapy efficacy [83].”
BackgroundSmeets, E., Dorst, D. N., Franssen, G. M., ESSEN, M. V., Frielink, C., Stommel, M. W. J., Trajkovic‐Arsic, M., Cheung, P. F., Siveke, J. T., Wilson, I., et al. (2023) · Cells · doi:10.3390/cells12101420 · Cited by 14
Aquino, A., & Franzese, O. (2025) · Cancers · doi:10.3390/cancers17091547 · Cited by 13
Sun, X., Zhang, X., He, Y., Du, X., Cai, Q., & Liu, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1562892 · Cited by 17
“For instance, experiments in mice showed that CD8 + T can promote apoptosis of fi broblasts (156).”
Xiong, J., Zhang, T., Lan, P., Zhang, S., & Fu, L. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.11 · Cited by 13
Baird, S. K., Rigopoulos, A., Cao, D., Allan, L. C., Renner, C., Scott, F. E., & Scott, A. M. (2015) · APOPTOSIS · doi:10.1007/s10495-015-1166-5 · Cited by 13
Keane, F. M., Chowdhury, S., Yao, T.-W., Nadvi, N. A., Gall, M. G., Chen, Y., Osborne, B., de Ribeiro, A. J. V., Church, W. B., McCaughan, G. W., et al. (2011) · Royal Society of Chemistry eBooks · doi:10.1039/9781849733151-00118 · Cited by 13
Woo, I. S., Hong, S. H., Byun, J. H., Kang, J.-H., Jeon, H., & Choi, M. (2008) · Cancer Investigation · doi:10.1080/07357900701684057 · Cited by 13
“In contrast to tumor cells, which are genetically unstable and mutate frequently, cancer-associated fibroblasts are more stable, making the stroma optimal target for cancer therapy (13).”
BackgroundFibroblast activation protein is dispensable in the anti-influenza immune response in mice
Tan, S., Chowdhury, S., Polak, N., Gorrell, M. D., & Weninger, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171194 · Cited by 14
“As a genetically stable molecule expressed on the cell surface and selectively upregulated on reactive stromal fibroblasts in a broad range of cancers, FAP is an attractive target for antitumour therapy [9, 47–49].”
Research progress on the role of fibroblast activation protein in diagnosis and treatment of cancer
Wu, Z., Hua, Y., Shen, Q., & Yu, C. (2022) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001565 · Cited by 12
The Role and Application of Fibroblast Activating Protein
Zhang, X.-L., Wang, X., Qian, J., Yang, W.-J., Xu, H., Xu, X.-D., & Zhang, G. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230530095305 · Cited by 12
Meng, J., Bao, W., Liu, M., Ma, Z., & Tian, Z. (2023) · Small · doi:10.1002/smll.202304491 · Cited by 16
Regulation of metaplasia and dysplasia in the stomach by the stromal microenvironment
Rhodes, J., Goldenring, J. R., & Lee, S. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01240-z · Cited by 14
“Using a DNA vaccine to target FAP on CAFs increased T-cell activity and the killing of CAFs, thereby decreasing the tumor burden 93 .”
BackgroundZhang, C., Li, H., Qian, B., Liu, C., Guo, F., & Lin, M. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.01.028 · Cited by 12
Li, M., Deng, Z., Xie, C., Chen, J., Yuan, Z., Rahhal, O., & Tang, Z. (2023) · Oral Diseases · doi:10.1111/odi.14602 · Cited by 11
Fibroblast activation protein: Pivoting cancer/chemotherapeutic insight towards heart failure
Gehris, J., Ervin, C., Hawkins, C., Womack, S. J., Churillo, A. M., Doyle, J., Sinusas, A. J., & Spinale, F. G. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115914 · Cited by 11
Wen, D., Wang, Y., Zhu, Z., Huang, Z., Cui, L., Wu, T., & Liu, C. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.165923 · Cited by 11
Moving Receptor Redirected Adoptive Cell Therapy Toward Fine Tuning of Antitumor Responses
Chicaybam, L., & Bonamino, M. (2014) · International Reviews of Immunology · doi:10.3109/08830185.2014.917412 · Cited by 13
“These properties led to the development of different strategies for elimination of this subset [105, 106].”
BackgroundHarati, K., Daigeler, A., Hirsch, T., Jacobsen, F., Behr, B., Wallner, C., Lehnhardt, M., & Becerikli, M. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2556 · Cited by 12
“A second mechanism of TAF-induced chemoresistance was detected by Loeffler et al (33).”
BackgroundHøye, E., Kanduri, C., Torgunrud, A., Lorenz, S., Edwin, B., Larsen, S. G., Fretland, Å. A., Dagenborg, V. J., Flatmark, K., & Lund‐Andersen, C. (2024) · Cancer Medicine · doi:10.1002/cam4.70521 · Cited by 12
“Potential interventions for CAFs include targeting surface markers such as FAP [44], DNA vaccines inducing CD8+ killing of CAFs, and CAR T cells engineered to target FAP [45, 46].”
Zhou, R., You, Z., & Liu, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1601013 · Cited by 13
Sliker, B. H., & Campbell, P. M. (2021) · Vaccines · doi:10.3390/vaccines9060634 · Cited by 13
“Thus, the use of this vaccine along with common chemotherapy drugs such as doxorubicin enhanced the effects of these agents as compared to single use alone and led to not only a decrease in primary tumor growth but also a 50% complete rejection of tumors in mouse models and a three-fold increase in survival [160].”
BackgroundMethodInfluentialHu, J., Jiang, Y., Wei, Q., Li, B., Xu, S., Guang, W., Li, P., Chen, W., Lv, W., Xiao, X., et al. (2022) · BioMed Research International · doi:10.1155/2022/2955359 · Cited by 10
“The propensity of CAFs to promote tumor growth makes them a potential immunotherapy target, according to studies [8 – 10].”
Benign non-immune cells in tumor microenvironment
Liu, S., Liu, C., He, Y., & Li, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561577 · Cited by 11
“A study showed that FAP-targeted vaccine effectively enhanced the CAFs-killing effect mediated by CD8 + T cells and increased drug uptake by colon cancer and BC (259).”
Zhang, N., Pan, F., Pan, L., Diao, W., Su, F., Huang, R., Yang, B., Li, Y., Qi, Z., Zhang, W., et al. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1167329 · Cited by 9
“, 2003), vaccines (Lee et al., 2005; Loeffler et al., 2006), immunoconjugates (Ostermann et al.”
Meng, F., Yin, Z., Lu, F., Wang, W., & Zhang, H. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15193 · Cited by 9
“10 Similarly, adoptive transfer of FAP-specific chimeric antigen receptor (CAR) T cells, inhibited the growth of connective tissue proliferative human lung cancer xenografts and syngeneic murine pancreatic cancer.”
BackgroundTovoli, F., Lorenzo, S. D., Barbera, M. A., Garajová, I., Frega, G., Palloni, A., Pantaleo, M. A., Biasco, G., & Brandi, G. (2017) · Future Oncology · doi:10.2217/fon-2017-0166 · Cited by 9
Gentile, S., Eskandari, N., Rieger, M. A., & Cuevas, B. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.609918 · Cited by 9
“Some reported examples include cancerassociated fibroblasts (CAFs) that promote tumor cell growth and metastasis (5), and tumor-associated macrophages forming a paracrine “pas de deux” with cancer cells to provoke mutual migration (6).”
BackgroundEcoevolutionary biology of pancreatic ductal adenocarcinoma
Arul, G. L. R., Toruner, M. D., Gatenby, R. A., & Carr, R. M. (2022) · Pancreatology · doi:10.1016/j.pan.2022.06.005 · Cited by 9
Wang, P., Zhang, H., Zhao, L., Zhang, Y., Li, F., Su, X., Jing, H., Lin, Z., & Zhang, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07340 · Cited by 8
Boinapalli, Y., Pandey, R. S., Chauhan, A. S., & Sudheesh, M. S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122579 · Cited by 9
Guo, Y., Chen, M., Yang, J., Zhou, W., Feng, G., Wang, Y., Ji, T., Zhang, Y., & Liu, Z. (2024) · Oral Diseases · doi:10.1111/odi.15130 · Cited by 9
The tumor microenvironment as a target for anticancer treatment
Bizzarri, M., Cucina, A., & Proietti, S. (2014) · Oncobiology and Targets · doi:10.4103/2395-4469.145341 · Cited by 8
“[111,112] Consequently, improved drug responses have been achieved when the collagen content in tumors has been reduced.[113]”
BackgroundFernandez, J. L. C., Benelli, R., Costa, D., Campioli, A., Tavella, S., Zocchi, M. R., & Poggi, A. D. (2023) · Cancers · doi:10.3390/cancers15030610 · Cited by 8
Fu, H., Guo, W., Huang, J., Wu, H., & Chen, H. (2023) · iRadiology · doi:10.1002/ird3.46 · Cited by 8
Triggering Tumor Immunity through Angiogenesis Targeting
Jinushi, M., & Dranoff, G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0880 · Cited by 9
Targeting the Tumor Microenvironment by Immunotherapy: Part 2
Leibovici, J., Itzhaki, O., Huszar, M., & Sinai, J. (2011) · Immunotherapy · doi:10.2217/imt.11.112 · Cited by 8
Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer
Aderonke, A. B., Ibrahim, R. B., & Huang, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184624 · Cited by 9
“A study showed that the anti-FAP CAR-T and DNA vaccine inhibits tumor growth in a mouse model of GI cancer [368,369].”
BackgroundCancer-associated fibroblasts and their significance in tumor progression
Oleynikova, N. A., Danilova, N. V., Mikhailov, I. А., Semina, E. V., & Malkov, P. G. (2020) · Russian Journal of Archive of Pathology · doi:10.17116/patol20208201168 · Cited by 8
Quenching thirst with poison? Paradoxical effect of anticancer drugs
Chai, K., Wang, C., Zhou, J., Mu, W., Gao, M., Fan, Z., & Lv, G. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106987 · Cited by 11
Cancer-associated fibroblasts: challenges and opportunities
Tavana, H., & Luker, G. D. (2023) · Oncotarget · doi:10.18632/oncotarget.28385 · Cited by 7
Batra, H. V., Ding, Q., Pandurengan, R. K., Ibarguen, H. P., Rabassedas, N. B., Şahin, A. A., Wistuba, I. I., Parra, E. R., & Raso, M. G. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1281650 · Cited by 7
“Fibroblast-like cells are the most abundant component in the breast cancerstromaplayingadynamicroleintumorigenesis(44,51,52).”
BackgroundLiu, G., Mo, E., Wang, X., Wu, N., Liu, F., Yuan, W., Chen, H., Wang, J., Xu, J., & Cai, S. (2015) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v14i5.21 · Cited by 7
“Fibroblast activation protein α (FAPα), a serine protease [7], is expressed in over 90 % of the stroma of malignant epithelial tumors, but not in normal tissues [8-10].”
BackgroundTang, M., Yang, M., He, K., Li, R., Chen, X., Wang, Y., Zhang, X., & Qiu, T. (2021) · Nanotechnology · doi:10.1088/1361-6528/abe076 · Cited by 7
“TAFS can also cause the body to develop therapeutic resistance [ 13 ] .”
Metadata
- Authors
- Loeffler, M.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Loeffler, M.
- ORCID
- Loeffler, M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1955-1962
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1481657
- OpenAlex
- W2002689409
- Cited by
- 633
- References
- 51
- Citations by year
- 2026: 17 · 2025: 27 · 2024: 41 · 2023: 58 · 2022: 33 · 2021: 56 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 32 · 2016: 39 · 2015: 46 · 2014: 33 · 2013: 33 · 2012: 28
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense
- National Institutes of Health
- National Cancer Institute (CA 83856, R01CA083856)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Peptidase Inhibition and Analysis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer-associated fibroblasts, fibroblast activation protein, oral DNA vaccine, type I collagen, tumor stroma, chemosensitization, multidrug resistance, colon cancer, breast cancer, metastasis, chemoimmunotherapy
- MeSH terms
- Fibroblast Activation Protein Alpha, Animals, Female, Fibroblasts, Membrane Proteins, Mice, Inbred BALB C, Neoplasms, Endopeptidases, Recombinant Fusion Proteins, Serine Endopeptidases, Survival Rate, Gelatinases, CD8-Positive T-Lymphocytes, Vaccines, DNA, Cancer Vaccines, Collagen Type I, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.